Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype londoninsider.co.uk
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer OncLive
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire
A woman in her 30s was admitted with 6 months of progressive shortness of breath and cyclical bilateral pleuritic chest pain associated with heavy, painful menstruation. She had a history …
To evaluate the feasibility of collagen-binding ⁶⁸Ga-CBP8 PET/MR for the noninvasive detection of deep infiltrating endometriosis.
Accumulating observational evidence suggests an association between thyroid function and endometriosis, though the causal relationship remains unclear. To investigate potential bidirectional causal relationships, including for endometriosis subtypes, we conducted a …
Polyunsaturated fatty acids (PUFAs) are hypothesized to modulate female reproductive endocrine disorders, yet their causal relationships remain elusive. We employed Mendelian randomization (MR) to investigate bidirectional causality between circulating PUFAs …
The identification of the appendix often presents a diagnostic challenge due to its significant anatomical variability, compounded by the frequency with which appendiceal pathologies manifest as atypical clinical presentations that …
To evaluate intraobserver and interobserver agreement in the interpretation of subtle MRI findings classified as minimal endometriosis, to assess the impact of the Kappa paradox in low-prevalence compartments, and to …